Unlocking barriers to further gene therapy success in eye disease

Cell & Gene Therapy Insights 2021; 7(12), 1751–1758


Published: 6 January 2022
Jed Chatterton

David McCall, Editor, Cell and Gene Therapy Insights, speaks to Jed Chatterton, Founder, RNAeye Consulting

Jed Chatterton, earned his PhD in Biochemistry from UCLA and did his post-doctoral training at MIT and The Burnham Institute. He has worked on nucleic acid therapeutics, including gene replacement, gene editing, and gene silencing, for over 20 years. His focus on ophthalmic indications began while working at Alcon, where he led a team developing therapeutic siRNAs to treat macular degeneration. He has since led programs targeting inherited retinal dystrophies at Precision Biosciences and Generation Bio. Most recently, he was VP of Gene Therapy at Gemini Therapeutics where he led a program developing a gene therapy approach to the treatment of geographic atrophy. He is currently working as a consultant with RNAeye Consulting.